New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil.
The present status, clinical experience, side effects, clinical pharmacology and electrophysiologic actions of seven new antiarrhythmic agents are reviewed. The drugs selected for comment are amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide and verapamil. Each drug has been shown to have clinical efficacy in suppressing cardiac arrhythmias.
D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D004206:Disopyramide / Q000627:therapeutic use; D004594:Electrophysiology; D006801:Humans; D008801:Mexiletine / Q000627:therapeutic use; D009025:Morpholines / Q000627:therapeutic use; D010640:Phenothiazines / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; D010640:Phenothiazines; D008801:Mexiletine; D001073:Aprindine; D014700:Verapamil; D004206:Disopyramide; D000638:Amiodarone